Head-to-head · free
Kyntra Bio, Inc. vs Lexeo Therapeutics, Inc. Common Stock
KYNB vs LXEO — return on capital, cash generation, margins and balance sheet side by side.
KYNB
2 / 3
measures where KYNB leads
LXEO
1 / 3
measures where LXEO leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | KYNB · FY2025 | LXEO · FY2025 |
|---|---|---|
| Revenue | $6.4M | — |
| Net income | $183.5M | (100.0M) |
| Revenue growth (yearly, multi-year) | -59.3% | — |
| Free cash flow | (4.8M) | (99.0M) |
| Free cash flow margin | -74.7% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | -55.0% |
| Gross margin | 91.4% | — |
| Operating margin | -704.1% | — |
| Net debt / EBITDA | 1.06x | 0.59x |
Figures are as reported by each company; latest fiscal year shown.
Where Kyntra Bio, Inc.'s cash went (FY2025)
- Capital spending
- $38000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Lexeo Therapeutics, Inc. Common Stock's cash went (FY2025)
- Capital spending
- $397000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free